Cediranib
Childhood Choroid Plexus Tumor
Pediatric Brain Tumor ConsortiumSmall moleculePhase 1Dormant
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Childhood Choroid Plexus Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FILGRASTIM Barbara Ann Karmanos Cancer Institute | Phase 3 | BB |
Irinotecan National Cancer Institute (NCI) | Phase 2 | BB |
DEXAMETHASONE National Cancer Institute (NCI) | Phase 1 | CCC |
(+)-VINCRISTINE National Cancer Institute (NCI) | Phase 1 | CCC |
Vorinostat National Cancer Institute (NCI) | Phase 1 | CCC |
View all 20 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →